2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 2661

Clinical Impact of Selenium and Vitamin C Deficiency in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2082

Clinical Presentation, Management, and Prognosis of Pseudogout in Prosthetic Joint Implant Patients: A Retrospective Study

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2475

Clinical Remission in Subjects with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab As Monotherapy or in Combination with Methotrexate or Other Synthetic Dmards: A Real-World Clinical Trial

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars

9:00AM-11:00AM: Abstract Number: 2160

Clinical Significance of Anti-Aminoacyl tRNA Synthetase Antibodies Which Are Positive By ELISA but Not By Immunoprecipitation – the Variations of Antigen Recognition and the Association with Interstitial Lung Diseases but Not Myositis –

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2407

Clinical Significance of Elevated Anti-Cyclic Citrullinated Protein Antibody Titers in Patients with Pulmonary Hypertension

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2097

Clinical Significance of KL-6 and SP-D As Serum Markers for Interstitial Lung Disease in Patients with Connective Tissue Disease

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2172

Clinical Significance of Serum Levels of Anti-Transcriptional Intermediary Factor 1-γ Antibody in Patients with Dermatomyositis

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2088

Clinical Significance of Urate Deposition in Tendon: A Dual-Energy CT Study

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2530

Clinical Specialty Setting As a Determinant for Disease Management in Patients with Psoriatic Arthritis: An Interim Analysis of the Cross-Sectional Observational Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

9:00AM-11:00AM: Abstract Number: 2163

Clinical Utilization Patterns and Performance of Commercial Myositis Autoantibody Panels in Routine Practice

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2176

Clusterin Is Upregulated in Muscle Tissue and Serum in Idiopathic Inflammatory Myopathies and Is Associated with Clinical Disease Activity

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2226

Cntx-4975 (Trans-Capsaicin) Injection Provides Clinically Meaningful Pain Reduction in Subjects with Painful Intermetatarsal Neuroma (Morton’s Neuroma): A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study

Pain – Basic and Clinical Aspects Poster

9:00AM-11:00AM: Abstract Number: 2225

Cntx-4975 (Trans-Capsaicin) Injection Provides Clinically Meaningful Pain Reduction in Subjects with Painful Intermetatarsal Neuroma (Morton’s Neuroma): An Open-Label, Ascending-Dose Study

Pain – Basic and Clinical Aspects Poster

9:00AM-11:00AM: Abstract Number: 2108

Colchicine Treatment May be Protective Against Ventricular Arrhythmias in FMF Patients

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2688

Collagen Metabolite Biomarker Levels Are Associated with the Amount of Fibrosis in Internal Organs in Systemic Sclerosis Patients

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].